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n the Failing Left and Right Ventricle of
atients Treated With Either Pulsatile or
ontinuous Flow-Type Ventricular Assist Devices
atteo Vatta, PHD,*† Sonny J. Stetson, BSC,‡§¶ Shinawe Jimenez, MD,* Mark L. Entman, MD,‡¶#
eorge P. Noon, MD,‡¶# Neil E. Bowles, PHD,* Jeffrey A. Towbin, MD,*§
uillermo Torre-Amione, MD, PHD‡§¶
ouston, Texas; and Trieste, Italy
OBJECTIVES We investigated the integrity of dystrophin in left ventricle (LV) and right ventricle (RV) of
patients with end-stage heart failure due to ischemic cardiomyopathy (IHD) or dilated
cardiomyopathy (DCM), and compared the efficacy of pulsatile or continuous flow assist
devices on dystrophin reverse remodeling.
BACKGROUND Recently we demonstrated that the amino (N)-terminus of dystrophin is preferentially
disrupted in failing LV myocardium irrespective the underlying etiology, and that this defect
is reversed by mechanical unloading using left ventricular assist device (LVAD) therapy.
METHODS Myocardial samples were obtained from seven normal controls, seven failing hearts (either
DCM or IHD), and 14 failing-heart patients who underwent placement of either pulsatile (7
patients) or continuous flow (7 patients) LVADs for progressive refractory HF. The
expression and integrity of dystrophin in these samples were determined by immunohisto-
chemistry using antibodies against the N-terminal and carboxyl (C)-terminal domains.
RESULTS Immunohistochemical staining identified disruption of the N-terminal dystrophin in both
LVs and RVs of all seven failing-heart patients, whereas the C-terminus was normal.
Furthermore, this disruption was reversed in 12 of the 14 patients after LVAD therapy using
either pulsatile or continuous devices; the degree of the reverse remodeling was similar in both
ventricles, although greater recovery was noted in patients treated with pulsatile flow devices.
CONCLUSIONS Integrity of the N-terminus of dystrophin is a useful indicator of both LV and RV function.
In addition to improving LV hemodynamics, LVAD therapy results in amelioration of the
myocardial structure of the right cardiac chamber. (J Am Coll Cardiol 2004;43:811–7)
© 2004 by the American College of Cardiology Foundationa
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pystrophin was originally identified as the gene responsible
or Duchenne´ and Becker muscular dystrophies (DMD/
MD) (1) and later for the X-linked form of dilated
ardiomyopathy (XLCM) (2). Typically, mutations in the
mino (N)-terminus of dystrophin have been reported in
atients with XLCM, whereas patients with DMD/BMD
ave mutations scattered throughout the gene. Dystrophin
inks the actin cytoskeletal networks and the sarcolemmal
ystrophin-associated protein complex (DAPC), which is
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Manuscript received April 16, 2003; revised manuscript received August 1, 2003,(ccepted September 22, 2003.ssociated with the extracellular matrix of the cardiomyo-
yte. Thus, dystrophin plays a key role in the transduction of
hysical forces in striated muscle (3). Dystrophin also
rovides an anchorage to the DAPC, as demonstrated in
MD patients in whom primary dystrophin deficiency
esults in destabilization of the entire complex (4). In
ddition, the lack of dystrophin is associated with altered
tructure and mechanical adherence of costameres to the
nderlying cytoskeletal actin network (5). Therefore, as
xpected, mutations in dystrophin, actin, or DAPC sub-
omplexes result in a wide spectrum of skeletal myopathy
nd/or cardiomyopathy in humans and animal models (6).
In our previous report, we demonstrated a selective
bnormality of the N-terminus of dystrophin in the myo-
ardium of the left ventricle (LV) of patients with end-stage
ardiomyopathy, regardless of the underlying etiology (7).
he integrity of dystrophin in the right ventricle (RV) was
ot investigated. In addition, chronic mechanical unloading
ith a pulsatile-type left ventricular assist device (LVAD)
esulted in reverse remodeling of dystrophin in the LV,
uggesting that there is an important role for dystrophin in
he development of ventricular dysfunction and that dystro-
hin can be used as a molecular marker for heart failure
HF) (7). Although LVAD therapy results in the amelio-
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Dystrophin in LV and RV After Either Pulsatile or Continuous LVAD Therapy March 3, 2004:811–7ation of the myocardial functional deficits and molecular
ecovery of the LV, it is unclear whether unloading the LV
an help the recovery of the RV. Further understanding of
he effects of prolonged LV unloading on the RV structure
ill increase our understanding of HF and potentially
rovide markers for myocardial recovery.
In this report, we evaluate the effect of LV mechanical
nloading on the failing RV by investigating the molecular
emodeling of the N-terminus of dystrophin. We demon-
trate that the use of either a pulsatile- or continuous-flow
VAD improves not only the failing LV but also the RV by
nducing normalization of dystrophin expression.
ETHODS
atient evaluation. Myocardial samples (RV and LV)
rom the explanted hearts of seven patients with either
schemic (IHD) or non-ischemic idiopathic dilated cardio-
yopathies (DCM) were obtained after informed consent.
eft ventricular and RV size and function were measured
sing M-mode and two-dimensional echocardiographic
mages, as previously described (8,9). All patients were listed
or cardiac transplantation at the Methodist Hospital/
aylor College of Medicine transplant program and were
unctional class IV using the New York Heart Association
lassification (10). Endomyocardial biopsy samples from
V and LV free walls were obtained after informed consent
rom 14 failing-heart patients undergoing treatment with
ither pulsatile (7 patients) or continuous flow (7 patients)
VADs. Normal myocardial samples (i.e., controls) were
btained from both ventricles by through-cut biopsy of
onor hearts before heart transplantation. The Baylor Col-
ege of Medicine Institutional Review Board fully approved
ll studies.
Myocardial samples were either snap-frozen in liquid
itrogen or fixed in 2% paraformaldehyde for 45 min,
ollowed by dehydration through increasing concentrations
f alcohols, then cleared through xylene for subsequent
mbedding in paraffin.
mmunohistochemistry. Sections (5 m) were cut from
rozen myocardial samples and stained using anti-
ystrophin antibodies (N-terminus- and C-terminus-
pecific: Novocastra, Newcastle, U.K.) (9). Each primary
Abbreviations and Acronyms
BMD  Becker muscular dystrophy
DAPC  dystrophin-associated protein complex
DMD  Duchenne´ muscular dystrophy
HF  heart failure
IHD  ischemic cardiomyopathy
LV  left ventricle/ventricular
LVAD  left ventricular assist device
N  amino
RV  right ventricle/ventricular
XLCM  X-linked form of dilated cardiomyopathyntibody (diluted 1:10 in phosphate-buffered saline) was sncubated with the sections for 30 min at room temperature.
fter washing, the slides were incubated for 15 min at room
emperature with the secondary antibody (FITC-
onjugated anti-mouse: Novocastra), diluted 1:400, and
hen mounted (9).
Analysis by three blinded observers led to a semi-
uantitative analysis of the staining intensity. Normal stain-
ng was graded as 4, whereas absence was graded as 0.
ntermediate staining intensity was graded as 3 (mildly
educed: 50% to 75% of normal), 2 (moderately reduced:
5% to 50% of normal), or 1 (severely reduced: 1% to 25%
f normal).
Fixed myocardial tissue sections were stained with picro-
irius red as previously described (11,12). Total collagen
ontent was measured as the sum of all areas stained within
he slide, including interstitial, perivascular, and micro-
copic scars. Myocyte size was determined using a comput-
rized edge detection system, as described previously (13).
tatistical analysis. Statistical comparisons between con-
rols and pre- and post-LVAD groups were performed with
Mann-Whitney U test to identify statistical significance
or myocyte size and collagen expression. Donor heart age
ifference was calculated by Wilcoxon rank-sum test. All
he data in the text and figures are expressed as mean SD.
ESULTS
linical characteristics of the study cohort. Table 1
hows the demographics of the patients enrolled in the
tudy and from whom end-stage myocardium was ob-
ained. Patents with DCM were younger (49.2  11.7
ears) than the IHD patients (53.6  10.3 years), but the
ifference was not statistically significant, although the
ower to detect a difference is very low owing to the small
umber of patients (p  0.3824). Fourteen patients
nderwent LVAD placement for progressive cardiac
eterioration, seven with pulsatile flow devices (Novacor,
orld Heart Inc., Oakland, California) and seven with
ontinuous flow devices (DeBakey-Noon Axial Flow
AD, MicroMed Technology, Inc., Houston, Texas).
ll LVAD-treated patients as well as five of seven
ailing-heart patients received maximal intravenous ino-
ropic support. In addition, six LVAD-treated patients
ad inotropic support even after LVAD implantation
Table 1). The duration of inotropic support for each
roup was the following: failing  14.9  12.6 days;
ontinuous  21.0  9.5 days; pulsatile  36.4  38.9
ays. However, this difference was not statistically sig-
ificant, perhaps owing to the limited cohort studied (p
0.25).
The mean duration of the LVAD support was 88.0 
7.5 days for the patients treated with pulsatile pump,
nd 40.14  31.2 days for those treated with a continu-
us flow pump. Also in this case, because of the small
umber of patients evaluated, the difference was not
tatistically significant (p  0.077). Histopathological
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March 3, 2004:811–7 Dystrophin in LV and RV After Either Pulsatile or Continuous LVAD Therapynalysis of patients who underwent mechanical support
ith either a continuous or pulsatile device showed
educed total collagen content in both the RV and LV
data not shown), as described elsewhere (14).
ystrophin expression in failing myocardium. Figure 1A,
hows representative immunostains for the N-terminus of
able 1. Patients’ Demographics and Hemodynamics Before Any
Age Gender
LVAD
Duration
(Days) Etiology
Pre-Tr
LVAD
Dura
ailing
F1 61 M N/A IHD
F2 53 F N/A DCM
F3 55 F N/A DCM
F4 29 F N/A DCM
F5 56 F N/A DCM
F6 67 M N/A DCM
F7 59 M N/A IHD
ontinuous
C1 41 M 93 IHD
C2 48 F 76 DCM
C3 59 M 30 IHD
C4 57 F 20 IHD
C5 49 M 19 IHD
C6 31 F 29 DCM
C7 53 F 14 DCM
ulsatile
P1 51 M 105 IHD
P2 46 M 32 DCM
P3 36 M 174 IHD
P4 65 M 96 DCM
P5 69 M 27 IHD
P6 45 M 40 DCM
P7 42 M 142 DCM
ean  SD.
DCM  idiopathic or familial dilated cardiomyopathy; IHD  ischemic heart d
igure 1. Dystrophin expression of normal and failing left ventricular (LV
etection of the amino (N)-terminus of dystrophin in normal control (LV
he immunohistochemical detection of N-terminus (B) and C-terminus (C) dyystrophin in LV and RV samples obtained from normal and
ailing myocardium. Strong staining of the sarcolemma is
pparent with the antibody against the N-terminal domain of
ystrophin in control sections but is absent in LV sections from
he failing heart and reduced in the RV of the same heart (Fig.
A). Amino-terminal dystrophin staining was significantly
gical Interventions
ant/Pre
tropes
(Days)
LVAD
Implantation
Post-LVAD Inotropes
Duration (Days) Transplant
N/A N/A YES
N/A N/A YES
N/A N/A YES
N/A N/A YES
N/A N/A YES
N/A N/A YES
N/A N/A YES
YES N/A YES
YES 44 YES
YES 29 YES
YES N/A YES
YES 19 YES
YES 30 YES
YES 14 YES
YES N/A YES
YES N/A YES
YES 87 YES
YES N/A YES
YES N/A YES
YES N/A YES
YES N/A YES
LVAD  left ventricular assist device; N/A  not applicable.
right ventricular (RV) samples. Selected immunohistochemistry for the
V) and failing (LV and RV) myocardial samples (A). Staining scores forSur
anspl
Ino
tion
23
13
N/A
11
23
N/A
34
15
16
34
24
22
6
30
11
N/A
38
83
98
15
10) and
and Rstrophin in samples from normal controls and failing hearts.
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Dystrophin in LV and RV After Either Pulsatile or Continuous LVAD Therapy March 3, 2004:811–7educed in the failing hearts with an average staining score of
.7  0.6 in LV samples and 1.9  0.4 in RV samples,
ompared to control myocardium with an average staining
core of 4.0  0.5 (p  0.001 for both ventricles: Fig. 1B). In
ontrast, staining for C-terminus dystrophin was indis-
inguishable between controls and failing myocardium
Fig. 1C).
ffect of the type of LVAD support on RV and LV
emodeling. Analysis of myocardial biopsy samples from
igure 2. Effect of mechanical support with either a pulsatile or continuo
entricular (RV) samples. Immunohistochemical detection of N-terminu
ontinuous flow devices, pulsatile flow devices, and normal controls (A)
yocardial samples from patients treated with continuous flow device
mmunohistochemical detection of N-terminus (C) and C-terminus (D) d
amples from patients treated with either continuous or pulsatile flow devatients treated with continuous flow (n  7) or pulsatile cow devices (n  7) demonstrated improved staining scores
n both LV and RV samples in six of seven patients treated
ith pulsatile-type assist devices and six of seven patients
reated with continuous-type assist devices, compared to
ailing hearts (Fig. 2A). The staining score for N-terminus
ystrophin in continuous flow device–treated patients was
.1  0.5 in LV and 3.0  0.3 in RV samples, whereas for
he patients treated with pulsatile flow devices, the score was
.9  0.3 in both LV and RV samples (Fig. 2B). In
pe left ventricular assist device on failing left ventricular (LV) and right
trophin in LV and RV myocardial samples from patients treated with
unohistochemical detection of C-terminus dystrophin in LV and RV
lsatile flow devices, and normal controls (B). Staining scores for the
hin in LV and RV samples from controls, failing hearts, and myocardialus-ty
s dys
. Imm
s, pu
ystrop
ices.ontrast, neither pulsatile nor continuous-type LVAD sup-
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March 3, 2004:811–7 Dystrophin in LV and RV After Either Pulsatile or Continuous LVAD Therapyort had an effect on C-terminus dystrophin expression,
hich was indistinguishable from both normal and failing-
eart samples (Figs. 2B and 2D; p  0.1).
The effect of prolonged mechanical support with a
ontinuous-type assist devices resulted in improvement
n the baseline N-terminus dystrophin staining score in
V (p  0.01) and RV (p  0.01) samples when
ompared with failing hearts. However, the N-terminus
till showed some disruption in the continuous flow-type
VAD-treated samples by comparison with control myo-
ardium (Table 2). In contrast, N-terminal dystrophin
taining for pulsatile-type LVAD-treated patients was
tatistically indistinguishable from that of the normal
ontrols (p  0.34: LV and RV) and significantly
mproved over the failing-heart samples (p  0.001 for
oth LV and RV; Table 2). Interestingly, the normaliza-
ion of dystrophin expression was greater in patients
reated with pulsatile-type LVAD than among those
reated with a continuous-type LVAD (Table 2).
ISCUSSION
e had previously demonstrated that LV failing myocar-
ium was characterized by the selective disruption of the
-terminus end of dystrophin. Furthermore, we demon-
trated that after prolonged LV unloading with a pulsatile-
ype LVAD, N-dystrophin expression normalized (7). The
ata presented in this article expand these previous obser-
ations by demonstrating that not only the LV but also the
ailing RV is characterized by selective disruption of the
-terminus of dystrophin and that unloading the LV with
ulsatile or continuous flow-type LVADs led to improve-
ents in N-dystrophin expression in left and right failing
entricles in most patients.
The importance of dystrophin in maintaining the
ntegrity of sarcolemma and thus of the entire muscle cell
uring contractile stress was previously suggested by
tudies in mdx mice, in which dystrophin-deficient mus-
les show an abnormally high level of sarcolemmal
upture during muscle contraction, demonstrating a
Table 2. Dystrophin Average Staining Scores i
Mechanical Support Therapy
N-TER LV
Failing 1.71  0.6
Continuous 3.1  0.5
Pulsatile 3.9  0.3
Control 4  0.5
N-terminus score
Failing vs. control LV p  0.00004
Failing vs. control RV p  0.000003
Continuous vs. control LV p  0.0269
Continuous vs. control RV p  0.0006
Pulsatile vs. control LV p  0.3370
Pulsatile vs. control RV p  0.3370
LV  left ventricle; RV  right ventricle; TER  terminueveral-fold increase in susceptibility to either stretch- or iontraction-induced sarcolemmal disruption when com-
ared with normal fibers (15).
The mechanisms leading to dystrophin remodeling are
nknown, but several explanations are plausible. First, the
emonstration that after LV unloading dystrophin expres-
ion normalizes suggests that mechanical stress is a major
echanism for disruption. Mechanical stress imposed by
yocyte hypertrophy and long-term, continuous contractile
orces may create a state of fragility of the dystrophin-actin
inding domain by inducing tertiary structural alterations in
ystrophin. Indeed, mechanical stress results in alterations
f gene expression that could lead to alterations in dystro-
hin expression in vivo (16,17). Second, although the
mprovement of RV N-dystrophin expression may be the
esult of hemodynamic or unloading conditions, it is also
ossible that improvements in the “cytokine milieu” result in
eactivation of the proteases responsible for the selective
isruption of N-terminal dystrophin. Indeed, it is known
hat the protease 2A of Coxsackievirus B3 (one of the major
auses of acquired DCM) can cleave dystrophin, leading to
isruption of the cytoskeleton in infected mouse hearts,
uggesting this is an important pathologic mechanism in
cquired DCM (18). Although in these studies, all of the
yocardial samples were negative for cardiotropic viruses
enterovirus, adenovirus, CMV, EBV, and parvovirus) by
CR analysis (data not shown), it is possible that viral
yocardial injury occurred before sampling (19).
Because a large portion of the failing samples and samples
btained from patients after LVAD are obtained during
notropic therapy, the question arises as to the possibility
hat dystrophin remodeling is influenced by either the
resence or absence of inotropic therapy. Germane to this
iscussion, it is crucial to recognize the following. When we
nalyzed dystrophin remodeling in patients who had re-
eived transplants without being supported by inotropes
efore transplant, we found decreased expression of
-terminus dystrophin just as among patients receiving
notropes. In addition, we analyzed dystrophin expression in
small subset of patients (n  6) who were receiving
d-Stage Cardiomyopathy and After
-TER RV C-TER LV C-TER RV
1.9  0.4 3.9  0.2 3.9  0.2
3  0.3 3.9  0.2 3.7  0.3
3.9  0.3 3.9  0.2 3.7  0.3
4  0.5 4  0.2 4  0.2n En
Nnotropes at the time of LVAD implant and continued to
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Dystrophin in LV and RV After Either Pulsatile or Continuous LVAD Therapy March 3, 2004:811–7eceive inotropes until the time of transplantation. Thus,
aired samples were available on patients that were con-
tantly treated with inotropes, and in at least two of those
atients there was also found an improvement on
-terminus dystrophin expression (data not shown). These
ata taken together provide strong evidence that the role of
notropic therapy in dystrophin remodeling is minimal at
est. In the present report, we studied the effect of two
odes of LVAD support with respect to their ability to
odify dystrophin expression. Pulsatile-type LVADs pro-
ide a greater degree of unloading and, on full support,
ypasses the aortic root and ejects directly into either the
scending or descending aorta, maintaining the pulsatility
ith high benefit to both myocardial oxygen balance and
ardiac output (20). Continuous-type LVADs, when in full
upport, will not allow blood flow through the aortic valve,
eading to a state of no pulsatility, and decreasing the
ffective systemic blood flow (21). Although full character-
zation of hemodynamic differences between these two
orms of support does not exist, observations by our group
uggest that the effect of LV unloading, as defined by the
hange in volumes or mass, provided by the continuous-type
f LVAD may not be of the same magnitude as the one
bserved for pulsatile-type LVADs (G. Torre-Amione,
ersonal communication, 2003). However, cellular regres-
ion of hypertrophy occurs in the myocardium using either
ontinuous or pulsatile flow devices, as we recently showed
y analyzing various markers in the failing RV after LVAD
upport (14). Additionally, the defect in dystrophin integ-
ity is significantly ameliorated in both the left and right
ailing ventricle when supported with a continuous type of
VAD. Although the degree of improvement was greater
or the patients supported with a pulsatile-type LVAD, it is
ifficult to establish definitive comparative statements, con-
idering the small number of patients studied in this report
nd the variability in length of LVAD support. Indeed,
lthough the differences were not statistically significant,
here was a trend toward longer support in pulsatile-treated
atients. To better address this question, we are actively
nvolved in a multi-center LVAD study group that will
llow us better definition of this and other questions of more
irect clinical relevance.
A limitation of the present study comes from the fact that
t was not possible to obtain intra-individual LV and RV
amples before and after therapy. However, in our previous
tudy, we demonstrated a similar pattern for dystrophin
emodeling, as we showed in the present report in intra-
ndividually LV pre- and post-LVAD biopsies. Therefore,
e believe that in the present study, we demonstrate the
eliability of N-terminal dystrophin detection as a marker
or both LV and RV ventricular remodeling.
There are two clear important observations from these
tudies: 1) that the failing RV is also characterized by
elective disruption of N-dystrophin, which is normalized
fter prolonged mechanical unloading; and 2) that there
oes not appear to be a significant difference in the cellularesponse of the myocardium to pulsatile or continuous flow
ypes of support. These findings may be of crucial impor-
ance when considering the potential applications of
VADs in the future. For example, when one considers the
ossibility of myocardial recovery after LVAD support, the
ode of support and the cellular changes induced by the
ype of LVAD on failing myocardium may determine the
ate or the magnitude of recovery. One could argue that for
ull myocardial recovery, normalization of dystrophin ex-
ression in the left and right failing ventricle may be a
rerequisite.
In summary, we have shown that, in patients with
nd-stage cardiomyopathies, the selective defect in the
-terminus end of dystrophin is present in both RV and LV
nd that this defect is reversible in both chambers after
rolonged mechanical circulatory support with either a
ulsatile or continuous-type of LVAD. These findings
uggest that the link from sarcomere to sarcolemma and
CM is essential for the retention of normal ventricular size
nd function, that the dystrophin-actin binding domain is
ossibly fragile, and that the analysis of dystrophin-actin
inding domain is important to the understanding of
hanges that occur with mechanical unloading.
eprint requests and correspondence: Dr. Guillermo Torre-
mione, Methodist DeBakey Heart Center and Baylor College of
edicine, 6550 Fannin, Ste. 1901, Houston, Texas 77030. E-
ail: gtorre@bcm.tmc.edu.
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